Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000189679 | SCV000243325 | benign | not specified | 2019-07-22 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Laboratory for Molecular Medicine, |
RCV000189679 | SCV000269860 | benign | not specified | 2015-07-16 | criteria provided, single submitter | clinical testing | p.Arg57Cys in exon 2 of TBC1D24: This variant is not expected to have clinical s ignificance it has been identified in 0.3% (182/65958) of European chromosomes b y the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs202162520). |
Eurofins Ntd Llc |
RCV000585579 | SCV000332349 | uncertain significance | not provided | 2017-02-08 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000340164 | SCV000396203 | likely benign | Familial infantile myoclonic epilepsy | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. |
Labcorp Genetics |
RCV001084629 | SCV000560545 | benign | Developmental and epileptic encephalopathy, 1; Autosomal dominant nonsyndromic hearing loss 65; Caused by mutation in the TBC1 domain family, member 24 | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000189679 | SCV000615752 | uncertain significance | not specified | 2016-10-17 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000585579 | SCV000692828 | likely benign | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | TBC1D24: BP4 |
Ambry Genetics | RCV002314614 | SCV000847922 | uncertain significance | Inborn genetic diseases | 2019-05-01 | criteria provided, single submitter | clinical testing | The p.R57C variant (also known as c.169C>T), located in coding exon 1 of the TBC1D24 gene, results from a C to T substitution at nucleotide position 169. The arginine at codon 57 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on data from gnomAD, the T allele has an overall frequency of approximately 0.18% (507/27762) total alleles studied. The highest observed frequency was 1.06% (107/10138) of Ashkenazi Jewish alleles. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
ARUP Laboratories, |
RCV000585579 | SCV004562323 | likely benign | not provided | 2023-09-11 | criteria provided, single submitter | clinical testing | |
Bioinformatics Core, |
RCV000656037 | SCV000588313 | pathogenic | Childhood epilepsy with centrotemporal spikes | 2017-01-01 | no assertion criteria provided | case-control | CAADphred>15 |
Genome |
RCV000585579 | SCV000840178 | not provided | not provided | no assertion provided | phenotyping only | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. | |
Prevention |
RCV004739558 | SCV005345456 | benign | TBC1D24-related disorder | 2024-06-25 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |